Cerebral amyloid angiopathy and alzheimer's disease

Hirosaki Medical Journal

Volumn 61, Issue SUPPL., 2010, Pages

  Ghiso, Jorge ^a,b   Tomidokoro, Yasushi ^c   Revesz, Tamas ^d   Frangione, Bias ^a,b   Rostagno, Agueda ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955883712     PISSN: 04391721     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (102)

1. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245-9.
2. Ghiso J, Frangione B. Amyloidosis and Alzheimer's disease. Adv Drug Delivery Rev 2002;54:1539-51.
3. Kang I, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-6.
4. Selkoe DJ, Wolfe MS. Presenililn: running with scissors in the membrane. Cell 2007;131:215-21
5. Thinakaran G, EH K. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008;283:29615-9.
6. Roher AE, Lowenson JD, Clarke S, et al. Beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 1993;90:10836-40.
7. Kokjohn TA, Roher A. Amyloid precursor protein transgenic mouse models and Alzheimr's disease: understanding the paradigms, limitations, and contributions. Alzheimers & Dementia 2009;5:340-7.
8. Levy E, Carman MD, Fernandez Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990;248:1124-6.
9. Maat-Schieman M, Roos R, van Duinen S. Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology 2005;25:288-97.
10. Bornebroek M, Haan J, Roos N. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): a review of the variety in phenotypic expression. Amyloid 1999;6:215-24.
11. Herzig MC, Winkler DT, Burgermeister P, et al. Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nature Neurosc 2004;7:954-60.
12. Zhang-Nunes SX, Maat-Schieman M, van Duinen S, et al. The cerebral β-amyloid angiopathies: Hereditary and sporadic. Brain Pathol 2006;16:30-9.
13. Gudmundsson G, Hallgrimsson J, Jonasson T, Bjarnason O. Hereditary cerebral hemorrhage with amyloidosis. Brain 1972;95:387404.
14. Levy E, Lopez-Otin C, Ghiso J, Geltner D, Frangione B. Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases. J Exp Med 1989;169:1771-8.
15. Ghiso J, Jensson O, Frangione B. Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C). Proc Natl Acad Sci USA 1986;83:2974-8.
16. Ghiso J, Pons-Estel B, Frangione B. Hereditary cerebral amyloid angiopathy: the amyloid contain a protein which is a variant of cystatin C, an inhibitor of lysosomal cysteine proteases. Biochem Biophys Res Comm 1986;136:548-54.
17. Levy E, Jascolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: Cell biology and animal models. Brain Pathol 2006;16:60-70.
18. Janowski R, Kozak M, Jankowska E, et al. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat Struct Biol 2001;8:316-20.
19. Janowski R, Kozak M, Abrahamson M, Grubb A, Jaskolski M. 3D Domain-swapped human cystatin C with amyloid like intermolecular P-sheets. Structure Function, and Bioinformatics 2005;61:570-8
20. Janowski R, Abrahamson M, Grubb A, Jaskolski M. Domain swapping in N-truncated cystatin C. J Mol Biol 2004;341:151-60.
21. Rostagno A, Tomidokoro Y, Lashley T, et al. Chromosome 13 dementias. Cell Mol Life Sci 2005;62:1814-25.
22. Ghiso J, Vidal R, Rostagno A, et al. Amyloidogen-esis in Familial British Dementia is associated with a genetic defect on chromosome 13. Molecular basis of dementia Edited by Growdon J, Wurtman R, Corkin S, Nitsch R. New York, New York Academy of Sciences, 2000, pp.84-92.
23. Matsuda S, Giliberto L, Matsuda Y, et al. The familial dementia BRI2 gene binds the Alzheimer's gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem 2005;280:28912-6.
24. Matsuda S, Giliberto L, Matsuda T, Mc-Gowan E, D'Adamio L. BRI2 inhibits amyloid beta peptide precursor protein processing by interfering with the docking of secretases to the substrate. J Neurosci 2008;28:8668-76.
25. Fotinopoulou A, Tsachaki M, Vlavaki M, et al. BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Ap) production. J Biol Chem 2005;280:30768-72.
26. Kim J, Miller VM, Levites Y, et al. BRI2 (Itm2b) inhibits AP deposition in vivo. J Neurosci 2008; 28:6030-6.
27. Worster-Drought C, Hill T, McMenemey W. Familial presenile dementia with spastic paralysis. J Neurol Psychopathol 1933;14:27-34.
28. Ghiso J, Holton J, Miravalle L, et al. Systemic amyloid deposits in Familial British Dementia. J Biol Chem 2001;276:43909-14.
29. Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999;399:776-81.
30. Vidal R, Ghiso J, Revesz T, et al. A decamer duplication in the 3' region of the BRI gene originates a new amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA 2000;97:4920-5.
31. Ghiso J, Rostagno A, Tomidokoro Y, et al. Genetic alterations of the BRI2 gene: familial British and Danish dementias. Brain Pathol 2006;16:71-9.
32. Holton J, Ghiso J, Lashley T, et al. Regional distribution of fibrillar and non-fibrillar ABri deposition and its association with neurofibrillary degeneration in Familial British Dementia. Am J Pathology 2001;158:515-26.
33. Holton J, Lashley T, Ghiso J, et al. Familial Danish Dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol 2002;61:254-67.
34. Tomidokoro Y, Lashley T, Rostagno A, et al. Familial Danish dementia: Co-existence of ADan and Aβ amyloid subunits in the absence of compact plaques. J Biol Chem 2005;280:36883-94.
35. Castano EM, Prelli F, Soto C, et al. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 142 in Alzheimer's disease. J Biol Chem 1996;271:32185-91.
36. Prelli F, Levy E, van Duinen SG, et al. Expression of a normal and variant Alzheimer's β-protein gene in amyloid of hereditary cerebral hemorrhage, Dutch type: DNA and protein diagnostic assays. Biochem Biophys Res Comm 1990;170:301-7.
37. Gabizon R, Telling G, Meiner Z, Halimi M, Kahana I, Prusiner SB. Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease. Nat Med 1996;2:59-64.
38. Ando Y, Ando E, Ohlsson P.-I, Olofsson A, Sandgren O, Suhr O, Terazaki H, Obayashi K, Lundgren E, Ando M, Negi A. Analysis of transthyretin amyloid fibrils from vitreous samples in familial amyloidotic polyneuropathy (Val30Met). Amyloid 1999;6:119-23.
39. Thylen C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E. Modification of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 1993;12:743-8.
40. Dwulet FE, Benson MD. Characterization of a transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). J Clin Invest 1986;78:880-6.
41. Yazaki M, Tokuda T, Nakamura A, Higashikata. T, Koyama J, Higuchi K, Harihara Y, Baba S, Kametani F, Ikeda S.-I. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000;274:702-6.
42. Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 2003;28:43842.
43. Frangione B, Wisniewski T, Tagliavini F, Bugiani O, Ghiso J. Alzheimer's disseasse and Dutch variant Opposing faces of a single coin. Alzheimer's disease: Advances in clinical and basic research. Edited by Corain B, Iqbal K, Nicolini B, et al. Chichester, England, John Wyley and Sons, 1993, pp387-96.
44. Wisniewski T, Golabek A A, Kida E, Wisniewski KE, Frangione B. Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol 1995;147:23844.
45. Roher AE, Lowenson JD, Clarke S, et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993;268:3072-83.
46. Saido T, Iwatsubo T, Mann DM, et al. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 1995;14:457-66.
47. Shimizu T, Fukuda H, Murayama S, Izumiyama N, Shirasawa T. Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. J Neurosci Res 2002;70:451-61.
48. Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis-the archetype of structural and pathogenic variability. J Struct Biol 2000;130:280-9.
49. Watanabe A, Takio K, Ihara Y. Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau. J Biol Chem 1999;274:7368-78.
50. Shin Y, Cho HS, Fukumoto H, et al. Abeta species, including IsoAsp23 Abeta, in Iowa-type familial. cerebral amyloid angiopathy. Acta neuropathol 2003;105:252-8.
51. Shimizu T, Fukuda H, Murayama S, Izumiyama N, Shirasawa T. Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. J Neurosci Res 2002;70:451-61.
52. Shin Y, Cho, H.S., Fukumoto, H., Shimizu, T., Shirasawa, T., Greenberg, S.M., Rebeck, G.W. Abeta species, including IsoAsp23 Abeta, in Iowa-type familial cerebral amyloid angiopathy. Acta Neuropathol (Berl) 2003;105:252-8.
53. Robinson NE, Robinson AB. Deamination of human proteins. Proc Natl Acad Sci U S A 2001;98:12409-13.
54. Lindner H, Helliger W. Age-dependent deami-dation of asparagine residues in proteins. Exp Gerontol 2001;36:1551-63.
55. Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE. Irreversible dimerization/ tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim Biophys Acta 1998;1406:291-8.
56. Mori H, Takio K, Ogawara M, Selkoe D. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 1992;267:17082-6.
57. Lalowski M, Golabek A, Lemere CA, et al. The "nonamyloidogenic" p3 fragment (amyloid betal7-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem 1996;271:33623-31.
58. Harigaya Y, Saido TC, Eckman CB, et al. Amyloid P protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Comm 2000;24:422-7.
59. Russo C, Violani E, Salis S, et al. Pyroglutamate-modified amyloid P-peptides-APN3(pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 2002;82:1480-9.
60. Naslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer Aβ amyloid peptide. variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994;91:8378-82.
61. Dong J, Atwood CS, Anderson VE, et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: raman microscopic evidence. Biochemistry 2003;42:2768-73.
62. Kuo Y-M, Kokjohn TA, Beach T, et al. Comparative analysis of amyloid-P chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 2001;276:12991-8.
63. Barnham KJ, Ciccotosto GD, Tickler AK, et al. Neurotoxic, redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 2003;278:429-595.
64. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ (142) and Aβ (25-35). J Am Chem Soc 2001; 123:5625-31.
65. Coria F, Castano EM, Prelli F, et al. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 1988;58:454-7.
66. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-8.
67. Kalaria RN, Galloway PG, Perry G. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol Appl Neurobiol 1991;17:189-201.
68. Veerhuis R, Boshuizen RS, Familian A. Amyloid associated proteins in Alzheimer's and prion disease. Curr Drug Targets CNS & Neurological Dis 2005:4:23548.
69. Rostagno A, Ghiso J. Amyloidosis. Encyclopedia of neurological sciences. Edited by Aminoff M, Daroff R. San Diego, Academic Press, 2003, pp 129-35.
70. Ghiso J, Rostagno A, Tomidokoro Y, et al. Familial British and Danish dementias. Amyloid proteins. The beta sheet conformation and disease. Edited by Sipe JD. Weinheim, Germany, Wiley-VCH Verlag GmbH & Co. KGaA, 2005, pp.515-26.
71. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541:163-6.
72. Yamada T, Kakihara T, Gejyo F, Okada M. A monoclonal antibody recognizing apolipoprotein E peptides in systemic amyloid deposits. Ann Clin Lab Sci 1994;24:243-9.
73. Kindy MS, King AR, Perry G, de Beer MC, de Beer FC. Association of apolipoprotein E with murine amyloid A protein amyloid. Lab Invest 1995;73:469-75.
74. Gallo G, Picken M, Frangione B, Buxbaum JN. Nonamyloidotic monoclonal immunoglobulin deposits lack amyloid P component. Mod Pathol 1988;1:453-6.
75. Gallo G, Wisniewski T, Choi-Miura NH, Ghiso J, Frangione B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathology 1994;145:526-30.
76. Rostagno A, Revesz T, Lashley T, et al. Complement activation in Chromosome 13 dementias: Similarities with Alzheimer's Disease. J Biol Chem 2003;277:49782-90.
77. Botto M, Hawkins PN, Bickerstaff MCM, et al. Amyloid deposition is delayed in mice with targeted deletion of serum amyloid P component. Nature Med 1997;3:855-9.
78. Holtzman DM, Bales KR, Wu S, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999;103:R15-R21.
79. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995;92:4299-303.
80. Wisniewski T, Castano EM, Golabek A A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J. Pathology 1993;145:1030-5.
81. LaDu MJ, Falduto MT, Manelli AM, et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994;269:23403-6.
82. Ma J, Yee A, Brewer HB Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichy-motrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994;392:924.
83. Webster S, O'Barr S, Rogers J. Enhanced aggregation and β structure of amyloid β peptide after coincubation with Clq. J Neurosci Res 1994;39:448-56.
84. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 1996;316:671-9.
85. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-53.
86. Farkas E, Luiten PGM. Cerebral microvascular pathology in aging and Alzheimer's disease. Progress Neurobiol 2001;64:575-611.
87. Bailey TL, Rivara CB, Rocher AB, Hof PR. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 2004;26:573-8.
88. de la Torre JC. Alzheimer's disease is a vasocog-nopathy: a new term to describe its nature. Neurol Res 2004;26:517-24
89. Gorelick PB. Risk factors for vascular dementia and Alzheimer's disease. Stroke 2004;35:2620-7.
90. Petty MA, Wettstein JG. Elements of cerebral microvascular ischaemia. Brain Res Rev 2001; 36:23-34
91. Cadavid D, Mena H, Koeller K, Frommelt RA. Cerebral beta amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol 2000;59:768-73.
92. Greenberg SM. Cerebral amyloid angiopathy and dementia:two amyloids are worse than one. Neurology 2002;58:1587-8.
93. Natte R, Maat-Schieman M, Haan J, et al. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol 2001;50:765-72.
94. Olichney JM, Hansen LA, Hofstetter CR, et al. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 1995;52:702-8.
95. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002;58:1629-34.
96. Snowdon DA, Greiner LH, Mortimer J A, et al. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. JAMA 1997; 277:813-7.
97. Winkler DT, BondolW L, Herzig MC, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci. 2001;21:1619-27.
98. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N England J Med 2000;342:240-5.
99. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Molec Cell Biol 2000;1:120-9.
100. Fossati S, Cam J, Meyerson J, et al. Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-P variants in cells composing the cerebral vessel walls. Faseb J 2010; 24:22941
101. Solito R, Corti F, Fossati S, et al. Dutch and Arctic mutant peptides of beta amyloid (1-40) differentially affect the FGF-2 pathway in brain endothelium. Exp Cell Res 2009;315:385-95.
102. Viana RJ, Nunes AF, Castro RE, et al. Taurour-sodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. Cell Mol Life Sci 2009;66:1094-104.